Disclosed herein are methods and compounds for treating a cancer is characterized with an elevated expression of thioredoxin reductase (TrxR) or an elevated expression of peroxiredoxin (PRDX). In some embodiments, also disclosed herein are methods of selecting subjects for treatment or monitoring the treatment progress based on a biomarker panel.

The disclosed technology relates to chemical entities for the detection of wounds, e.g., chronic wounds or infected wounds, including compositions, substrates, kits, dressing materials, and articles, and systems containing such compounds. The disclosed technology further relates to methods of using these compositions, kits and systems in diagnostic assays, and in the diagnosis and/or detection of chronic or infected wounds based on enzymatic action on specific moieties and/or reaction sites. The disclosed technology additionally relates to detection of pathogenic, e.g., bacterial and/or viral substances, such as enzymes and substrates, at the wound situs. Additional disclosure relates to methods of characterizing wounds based on expression of a plurality of markers and using such information to treat, manage, and follow-up patients suffering from chronic or infected wounds.

Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.

Disclosed are a kit for testing myocardial infarction rapidly and a preparation method and use thereof. The kit comprises a strip capable of detecting three markers, namely, human myeloperoxidase (MPO), heart-fatty acid binding protein (FABP3) and cardiac troponin I (cTnI) simultaneously. The strip comprises a sample pad, a conjugate pad, a chromatographic membrane coated with three test lines and a quality control line, and a sample absorption pad. Antibodies of the three markers are all marked on the conjugate pad. The chromatographic membrane has three test lines formed by coating paired antibodies of the three markers respectively, the paired antibodies of the three markers being able to specifically combine with the three markers, respectively. The kit has advantages such as convenient operation, rapid response, high sensitivity and high specificity, point of care test, and economical and practical etc.

Reagents, assays, methods, kits, devices, and systems for rapid measurement of cholesterol and cholesterol sub-fractions from a blood sample are provided. Total cholesterol, low density lipoprotein cholesterol, and high density lipoprotein cholesterol can be measured in a single assay using kinetic measurements, under conditions in which cholesterol sub-species are converted to a detectable product at distinct rates. The detectable product is measured at different times after assay initiation. A lipase, cholesterol esterase, cholesterol oxidase and a peroxidase may be used together to produce colored product in amounts directly proportional to the quantity of cholesterol converted. Methods for calculating very-low density lipoprotein cholesterol levels by further including triglyceride measurements are disclosed. Assays may be performed in a single reaction mixture, allowing more accurate and precise cholesterol determinations, including ratios of cholesterol sub-fractions to total cholesterol, at less expense, than would be expected by performing several different assays in different reaction mixtures.

The present invention relates to the use of at least two of 2-Cys-PRDXs selected from a group consisting of PRDX1, PRDX2, PRDX3, PRDX4 and PRDX5 as a biomarker to diagnose, differentiate and/or assess the risk of chronic kidney disease (CKD). The present invention also relates to a method of diagnosis and a method of determining an increased risk of chronic kidney disease (CKD). A kit suitable for diagnosis and differentiation of chronic kidney disease (CKD) selected from the group comprising lupus nephritis (LN), IgA nephropathy (IgAN) and autosomal-dominant polycystic kidney disease (ADPKD) in a subject is also provided.

Self-indicating chemistries are provided for visual detection by a user of efficacious levels of peroxycarboxylic acid concentrations in a solution produced in situ. The self-indicating chemistries include a combination of dyes providing a visual color indication, such as a tri-color indicator system, such as a yellow, green, and red color system indicating in situ threshold levels of peroxycarboxylic acid concentrations in a solution employing the self-indicating chemistry. Systems, kits and compositions for a quantitative assessment of an in situ perhydrolysis reaction to generate peroxycarboxylic acids are provided. Methods of use are further provided.

The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.

The claimed invention relates to mobile computing monitoring of health statistics using chemically synthesized conjugate markers providing highly specific details of personal health states. Using portable computing and communications devices, commonly known as smartphones, personal health and wellness information is gathered from chemical markers and reported to the user. Chemical markers include chemicals which undergo a measurable color change when combined with body fluids such as saliva. Health information derived from chemical markers may be optically collected, locally reported and widely broadcast over a cloud based internet data distribution system.

A method for testing a sample for the presence of one or more targets comprises multiplexed catalyzed reporter deposition (CARD) is provided.